View ValuationWindlas Biotech 将来の成長Future 基準チェック /06現在、 Windlas Biotechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長23.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 23Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.22b (up 21% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.2% (down from 8.0% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 15Windlas Biotech Limited to Report Q4, 2026 Results on May 21, 2026Windlas Biotech Limited announced that they will report Q4, 2026 results on May 21, 2026分析記事 • May 13Windlas Biotech (NSE:WINDLAS) Ticks All The Boxes When It Comes To Earnings GrowthThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...お知らせ • Apr 17Windlas Biotech Limited (NSEI:WINDLAS) announces an Equity Buyback for 470,000 shares, representing 2.23% for INR 470 million.Windlas Biotech Limited (NSEI:WINDLAS) announces a share repurchase program. Under the program, the company will repurchase up to 470,000 shares, representing 2.23% of its issued share capital, for INR 470 million. The company will repurchase the shares at a price of INR 1,000 per equity share, payable in cash. The buyback is proposed to be made on a proportionate basis. The 15% of the number of equity shares which the company proposes to repurchase or number of equity shares entitled as per the shareholding of small shareholders as on the record date, whichever is higher, shall be reserved for the small shareholders. The record date for the purpose of ascertaining the eligibility of shareholders for the repurchase of shares is April 24, 2026. As of March 31, 2026, the company had 21,106,229 shares outstanding.Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹7.12 (vs ₹7.45 in 3Q 2025)Third quarter 2026 results: EPS: ₹7.12 (down from ₹7.45 in 3Q 2025). Revenue: ₹2.38b (up 22% from 3Q 2025). Net income: ₹150.0m (down 3.7% from 3Q 2025). Profit margin: 6.3% (down from 8.0% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 28Windlas Biotech Limited to Report Q3, 2026 Results on Feb 05, 2026Windlas Biotech Limited announced that they will report Q3, 2026 results on Feb 05, 2026分析記事 • Jan 17Windlas Biotech Limited's (NSE:WINDLAS) Popularity With Investors Is Under Threat From OverpricingWith a median price-to-earnings (or "P/E") ratio of close to 25x in India, you could be forgiven for feeling...分析記事 • Nov 14Solid Earnings May Not Tell The Whole Story For Windlas Biotech (NSE:WINDLAS)The market shrugged off Windlas Biotech Limited's ( NSE:WINDLAS ) solid earnings report. We think that investors might...分析記事 • Nov 11Here's Why We Think Windlas Biotech (NSE:WINDLAS) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Reported Earnings • Nov 07Second quarter 2026 earnings released: EPS: ₹8.48 (vs ₹7.49 in 2Q 2025)Second quarter 2026 results: EPS: ₹8.48 (up from ₹7.49 in 2Q 2025). Revenue: ₹2.26b (up 21% from 2Q 2025). Net income: ₹178.0m (up 14% from 2Q 2025). Profit margin: 7.9% (down from 8.4% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 29Windlas Biotech Limited to Report Q2, 2026 Results on Nov 06, 2025Windlas Biotech Limited announced that they will report Q2, 2026 results on Nov 06, 2025Reported Earnings • Aug 13First quarter 2026 earnings released: EPS: ₹8.43 (vs ₹6.47 in 1Q 2025)First quarter 2026 results: EPS: ₹8.43 (up from ₹6.47 in 1Q 2025). Revenue: ₹2.15b (up 23% from 1Q 2025). Net income: ₹176.6m (up 31% from 1Q 2025). Profit margin: 8.2% (up from 7.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 09Windlas Biotech Limited to Report Q1, 2026 Results on Aug 12, 2025Windlas Biotech Limited announced that they will report Q1, 2026 results on Aug 12, 2025お知らせ • Jul 29Windlas Biotech Limited Approves Final Dividend for the Financial Year 2024-25Windlas Biotech Limited announced that at the AGM held on July 28, 2025 approved Final Dividend of INR 5.80/- per Equity Share for the financial year 2024-25.分析記事 • Jul 22It Looks Like The CEO Of Windlas Biotech Limited (NSE:WINDLAS) May Be Underpaid Compared To PeersKey Insights Windlas Biotech's Annual General Meeting to take place on 28th of July Total pay for CEO Komal Gupta...Upcoming Dividend • Jul 14Upcoming dividend of ₹5.80 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 27 August 2025. Payout ratio is a comfortable 20% and the cash payout ratio is 76%. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.4%).お知らせ • Jul 06Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025, at 13:00 Indian Standard Time.Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹29.19 (vs ₹27.97 in FY 2024)Full year 2025 results: EPS: ₹29.19 (up from ₹27.97 in FY 2024). Revenue: ₹7.78b (up 23% from FY 2024). Net income: ₹609.9m (up 4.8% from FY 2024). Profit margin: 7.8% (down from 9.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 14Windlas Biotech Limited to Report Q4, 2025 Results on May 22, 2025Windlas Biotech Limited announced that they will report Q4, 2025 results on May 22, 2025Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,070, the stock trades at a trailing P/E ratio of 36.2x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 318% over the past three years.分析記事 • Mar 25Should You Be Adding Windlas Biotech (NSE:WINDLAS) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Feb 26Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹821, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 248% over the past three years.分析記事 • Feb 19What You Can Learn From Windlas Biotech Limited's (NSE:WINDLAS) P/E After Its 28% Share Price CrashThe Windlas Biotech Limited ( NSE:WINDLAS ) share price has fared very poorly over the last month, falling by a...Reported Earnings • Feb 12Third quarter 2025 earnings released: EPS: ₹7.45 (vs ₹7.26 in 3Q 2024)Third quarter 2025 results: EPS: ₹7.45 (up from ₹7.26 in 3Q 2024). Revenue: ₹1.95b (up 20% from 3Q 2024). Net income: ₹155.8m (up 3.2% from 3Q 2024). Profit margin: 8.0% (down from 9.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹842, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 52x in the Life Sciences industry in India. Total returns to shareholders of 227% over the past three years.お知らせ • Feb 03Windlas Biotech Limited to Report Q3, 2025 Results on Feb 11, 2025Windlas Biotech Limited announced that they will report Q3, 2025 results on Feb 11, 2025分析記事 • Jan 28Windlas Biotech (NSE:WINDLAS) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jan 10Windlas Biotech Limited Receives Good Manufacturing Practices Certification for New Injectable Facility from the Food Safety & Drugs Administration Authority of UttarakhandWindlas Biotech Limited announced that it has received Good Manufacturing Practices (GMP) certification for its new Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines.分析記事 • Nov 20There May Be Underlying Issues With The Quality Of Windlas Biotech's (NSE:WINDLAS) EarningsDespite posting some strong earnings, the market for Windlas Biotech Limited's ( NSE:WINDLAS ) stock hasn't moved much...Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹7.49 (vs ₹6.75 in 2Q 2024)Second quarter 2025 results: EPS: ₹7.49 (up from ₹6.75 in 2Q 2024). Revenue: ₹1.92b (up 26% from 2Q 2024). Net income: ₹156.6m (up 12% from 2Q 2024). Profit margin: 8.2% (down from 9.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Nov 05Windlas Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024Windlas Biotech Limited announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,116, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 272% over the past three years.分析記事 • Nov 01Windlas Biotech Limited's (NSE:WINDLAS) 30% Share Price Surge Not Quite Adding UpWindlas Biotech Limited ( NSE:WINDLAS ) shares have continued their recent momentum with a 30% gain in the last month...Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹998, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 51x in the Life Sciences industry in India. Total returns to shareholders of 203% over the past three years.お知らせ • Sep 26Windlas Biotech Limited Approves Final Dividend for the Financial Year 2023-24Windlas Biotech Limited at its AGM held on September 24, 2024, approved final dividend of INR 5.50 per equity share for the financial year 2023-24.分析記事 • Sep 01Windlas Biotech (NSE:WINDLAS) Will Pay A Larger Dividend Than Last Year At ₹5.50Windlas Biotech Limited's ( NSE:WINDLAS ) dividend will be increasing from last year's payment of the same period to...Declared Dividend • Aug 31Dividend increased to ₹5.50Dividend of ₹5.50 is 38% higher than last year. Ex-date: 17th September 2024 Payment date: 24th October 2024 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 25% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 79% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years.お知らせ • Aug 30Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024, at 14:30 Indian Standard Time.お知らせ • Aug 29Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2023-24Windlas Biotech Limited at the AGM to be held on September 24, 2024, the shareholders proposed a final dividend of INR 5.50 per equity share for the financial year 2023-24.Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹6.47 (vs ₹5.79 in 1Q 2024)First quarter 2025 results: EPS: ₹6.47 (up from ₹5.79 in 1Q 2024). Revenue: ₹1.79b (up 24% from 1Q 2024). Net income: ₹134.8m (up 12% from 1Q 2024). Profit margin: 7.5% (down from 8.3% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Aug 13Windlas Biotech Limited (NSE:WINDLAS) Stock Rockets 26% But Many Are Still Ignoring The CompanyDespite an already strong run, Windlas Biotech Limited ( NSE:WINDLAS ) shares have been powering on, with a gain of 26...お知らせ • Aug 02Windlas Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024Windlas Biotech Limited announced that they will report Q1, 2025 results on Aug 13, 2024Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹798, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 42x in the Life Sciences industry in India. Total returns to shareholders of 142% over the past year.分析記事 • Jul 30Should You Be Adding Windlas Biotech (NSE:WINDLAS) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Jun 07Even With A 27% Surge, Cautious Investors Are Not Rewarding Windlas Biotech Limited's (NSE:WINDLAS) Performance CompletelyWindlas Biotech Limited ( NSE:WINDLAS ) shares have had a really impressive month, gaining 27% after a shaky period...Reported Earnings • May 21Full year 2024 earnings released: EPS: ₹27.97 (vs ₹19.70 in FY 2023)Full year 2024 results: EPS: ₹27.97 (up from ₹19.70 in FY 2023). Revenue: ₹6.44b (up 26% from FY 2023). Net income: ₹581.9m (up 37% from FY 2023). Profit margin: 9.0% (up from 8.3% in FY 2023). The increase in margin was driven by higher revenue.Buy Or Sell Opportunity • May 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.2% to ₹553. The fair value is estimated to be ₹457, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.お知らせ • May 12Windlas Biotech Limited to Report Q4, 2024 Results on May 20, 2024Windlas Biotech Limited announced that they will report Q4, 2024 results on May 20, 2024Buy Or Sell Opportunity • Apr 30Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to ₹553. The fair value is estimated to be ₹458, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.Buy Or Sell Opportunity • Apr 22Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to ₹568. The fair value is estimated to be ₹462, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.Buy Or Sell Opportunity • Apr 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to ₹559. The fair value is estimated to be ₹460, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.New Risk • Mar 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.1% average weekly change).Buy Or Sell Opportunity • Feb 23Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to ₹547. The fair value is estimated to be ₹456, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.Reported Earnings • Feb 09Third quarter 2024 earnings released: EPS: ₹7.26 (vs ₹4.23 in 3Q 2023)Third quarter 2024 results: EPS: ₹7.26 (up from ₹4.23 in 3Q 2023). Revenue: ₹1.65b (up 38% from 3Q 2023). Net income: ₹151.0m (up 64% from 3Q 2023). Profit margin: 9.1% (up from 7.7% in 3Q 2023). The increase in margin was driven by higher revenue.お知らせ • Jan 31Windlas Biotech Limited to Report Q3, 2024 Results on Feb 08, 2024Windlas Biotech Limited announced that they will report Q3, 2024 results on Feb 08, 2024Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹528, the stock trades at a trailing P/E ratio of 23.5x. Average trailing P/E is 22x in the Life Sciences industry in India. Total returns to shareholders of 118% over the past year.Reported Earnings • Nov 14Second quarter 2024 earnings released: EPS: ₹6.75 (vs ₹5.59 in 2Q 2023)Second quarter 2024 results: EPS: ₹6.75 (up from ₹5.59 in 2Q 2023). Revenue: ₹1.56b (up 18% from 2Q 2023). Net income: ₹140.3m (up 15% from 2Q 2023). Profit margin: 9.0% (down from 9.2% in 2Q 2023). The decrease in margin was driven by higher expenses.分析記事 • Nov 03Is Now The Time To Put Windlas Biotech (NSE:WINDLAS) On Your Watchlist?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...お知らせ • Oct 31Windlas Biotech Limited to Report First Half, 2024 Results on Nov 08, 2023Windlas Biotech Limited announced that they will report first half, 2024 results on Nov 08, 2023お知らせ • Sep 13Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23Windlas Biotech Limited at the AGM held on September 12, 2023, the shareholders approved a final dividend of INR 4 per equity share for the financial year 2022-23.Upcoming Dividend • Aug 29Upcoming dividend of ₹4.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 05 September 2023. Payment date: 12 October 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.6%).分析記事 • Aug 20Windlas Biotech (NSE:WINDLAS) Is Increasing Its Dividend To ₹4.00Windlas Biotech Limited's ( NSE:WINDLAS ) dividend will be increasing from last year's payment of the same period to...お知らせ • Aug 19+ 1 more updateWindlas Biotech Limited, Annual General Meeting, Sep 12, 2023Windlas Biotech Limited, Annual General Meeting, Sep 12, 2023, at 12:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2023, together with the Reports of the Auditors and the Board of Directors thereon; to consider declare a Final Dividend; to consider and appoint a Director in place of Mr. Hitesh Windlass, Managing Director who is liable to retire by rotation and being eligible, offers himself for re-appointment; and to transact such other business matters.Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹384, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 82% over the past year.Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: ₹5.79 (vs ₹4.50 in 1Q 2023)First quarter 2024 results: EPS: ₹5.79 (up from ₹4.50 in 1Q 2023). Revenue: ₹1.47b (up 23% from 1Q 2023). Net income: ₹120.7m (up 23% from 1Q 2023). Profit margin: 8.2% (in line with 1Q 2023).お知らせ • Aug 01Windlas Biotech Limited to Report Q1, 2024 Results on Aug 08, 2023Windlas Biotech Limited announced that they will report Q1, 2024 results on Aug 08, 2023Reported Earnings • May 06Full year 2023 earnings released: EPS: ₹19.70 (vs ₹18.58 in FY 2022)Full year 2023 results: EPS: ₹19.70 (up from ₹18.58 in FY 2022). Revenue: ₹5.23b (up 12% from FY 2022). Net income: ₹426.3m (up 12% from FY 2022). Profit margin: 8.1% (down from 8.2% in FY 2022). The decrease in margin was driven by higher expenses.お知らせ • May 06Windlas Biotech Limited Recommends DividendWindlas Biotech Limited at its board meeting held on May 5, 2023 Recommended a Dividend of INR 4.00/- per Equity Share of face value of INR 5/- each. The said dividend, if declared by the Members of the Company at the ensuing Annual General Meeting (AGM), will be credited/despatched within three weeks of the conclusion of said AGM.お知らせ • Feb 10Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive OfficerWindlas Biotech Limited announced that on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on February 08, 2023, approved the appointment of Ms. Komal Gupta as the Chief Executive Officer and Key Managerial Personnel of the Company with effect from February 08, 2023. Ms. Komal Gupta holds a bachelor's degree in commerce from Dr. Babasaheb Ambedkar Marathwada University. She is a fellow member of the Institute of Chartered Accountants of India, an associate member of the Institute of Company Secretaries of India and the Institute of Cost and Works Accountants of India. She has experience in the field of finance. She joined the Company on October 16, 2015. She is currently the Chief Financial Officer of the Company and she will continue as Chief Financial Officer till a suitable person is appointed. Ms. Komal Gupta has an extensive experience in the field of Finance, Accounts, Taxation, Business Finance, Treasury and Compliance. Prior to joining the Company, she has worked with Anand Automotives Group (Perfect Circle India Limited, Mahle Filters Limited, Corporate office Anand Automotive Systems Limited) and DSM Group (DSM Sinochem Pharmaceuticals India Pvt. Ltd., now Centrient Pharmaceuticals India Pvt. Ltd.).Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: ₹4.23 (vs ₹3.81 in 3Q 2022)Third quarter 2023 results: EPS: ₹4.23 (up from ₹3.81 in 3Q 2022). Revenue: ₹1.22b (up 3.6% from 3Q 2022). Net income: ₹91.9m (up 11% from 3Q 2022). Profit margin: 7.5% (up from 7.1% in 3Q 2022). The increase in margin was driven by higher revenue.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 09Second quarter 2023 earnings released: EPS: ₹5.59 (vs ₹4.11 in 2Q 2022)Second quarter 2023 results: EPS: ₹5.59 (up from ₹4.11 in 2Q 2022). Revenue: ₹1.35b (up 17% from 2Q 2022). Net income: ₹121.9m (up 47% from 2Q 2022). Profit margin: 9.0% (up from 7.2% in 2Q 2022). The increase in margin was driven by higher revenue.お知らせ • Aug 27+ 1 more updateWindlas Biotech Limited to Report Fiscal Year 2023 Results on May 30, 2023Windlas Biotech Limited announced that they will report fiscal year 2023 results on May 30, 2023Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹4.50 (vs ₹3.67 in 1Q 2022)First quarter 2023 results: EPS: ₹4.50 (up from ₹3.67 in 1Q 2022). Revenue: ₹1.23b (up 11% from 1Q 2022). Net income: ₹98.0m (up 47% from 1Q 2022). Profit margin: 8.0% (up from 6.0% in 1Q 2022). The increase in margin was driven by higher revenue.分析記事 • May 23Windlas Biotech (NSE:WINDLAS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfWindlas Biotech Limited's ( NSE:WINDLAS ) robust earnings report didn't manage to move the market for its stock. We did...Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹243, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 36x in the Life Sciences industry in India.分析記事 • Apr 07Windlas Biotech Limited's (NSE:WINDLAS) Shares Lagging The Market But So Is The BusinessWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 22x, you may consider...Reported Earnings • Feb 03Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹3.81 (down from ₹6.75 in 3Q 2021). Revenue: ₹1.19b (up 1.0% from 3Q 2021). Net income: ₹83.1m (down 32% from 3Q 2021). Profit margin: 7.0% (down from 10% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.Reported Earnings • Sep 12First quarter 2022 earnings released: EPS ₹3.67 (vs ₹0.25 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹1.11b (up 50% from 1Q 2021). Net income: ₹66.9m (up ₹62.2m from 1Q 2021). Profit margin: 6.0% (up from 0.6% in 1Q 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹398, the stock trades at a trailing P/E ratio of 39.6x. Average trailing P/E is 45x in the Life Sciences industry in India.Board Change • Aug 17Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Windlas Biotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NSEI:WINDLAS - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20269,0416653731,049N/A12/31/20258,683667N/AN/AN/A9/30/20258,302673440945N/A6/30/20257,948652N/AN/AN/A3/31/20257,599610160682N/A12/31/20247,285617N/AN/AN/A9/30/20246,957612317849N/A6/30/20246,613596N/AN/AN/A3/31/20246,3105827131,090N/A12/31/20236,004526N/AN/AN/A9/30/20235,579467184938N/A6/30/20235,379449N/AN/AN/A3/31/20235,131426-99610N/A12/31/20224,945460N/AN/AN/A9/30/20224,924451-17349N/A6/30/20224,749412N/AN/AN/A3/31/20224,659381-5791N/A12/31/20214,506292N/AN/AN/A9/30/20214,50233248118N/A6/30/20214,363343N/AN/AN/A3/31/20214,27615856115N/A12/31/20203,94810447135N/A3/31/20203,28916297250N/A3/31/20193,073638N/A187N/A3/31/20183,522112N/A349N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: WINDLASの予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: WINDLASの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: WINDLASの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: WINDLASの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: WINDLASの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: WINDLASの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/21 08:48終値2026/06/19 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Windlas Biotech Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)Full year 2026 results: EPS: ₹31.60 (up from ₹29.19 in FY 2025). Revenue: ₹9.22b (up 21% from FY 2025). Net income: ₹664.6m (up 9.0% from FY 2025). Profit margin: 7.2% (down from 8.0% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 15Windlas Biotech Limited to Report Q4, 2026 Results on May 21, 2026Windlas Biotech Limited announced that they will report Q4, 2026 results on May 21, 2026
分析記事 • May 13Windlas Biotech (NSE:WINDLAS) Ticks All The Boxes When It Comes To Earnings GrowthThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
お知らせ • Apr 17Windlas Biotech Limited (NSEI:WINDLAS) announces an Equity Buyback for 470,000 shares, representing 2.23% for INR 470 million.Windlas Biotech Limited (NSEI:WINDLAS) announces a share repurchase program. Under the program, the company will repurchase up to 470,000 shares, representing 2.23% of its issued share capital, for INR 470 million. The company will repurchase the shares at a price of INR 1,000 per equity share, payable in cash. The buyback is proposed to be made on a proportionate basis. The 15% of the number of equity shares which the company proposes to repurchase or number of equity shares entitled as per the shareholding of small shareholders as on the record date, whichever is higher, shall be reserved for the small shareholders. The record date for the purpose of ascertaining the eligibility of shareholders for the repurchase of shares is April 24, 2026. As of March 31, 2026, the company had 21,106,229 shares outstanding.
Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹7.12 (vs ₹7.45 in 3Q 2025)Third quarter 2026 results: EPS: ₹7.12 (down from ₹7.45 in 3Q 2025). Revenue: ₹2.38b (up 22% from 3Q 2025). Net income: ₹150.0m (down 3.7% from 3Q 2025). Profit margin: 6.3% (down from 8.0% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 28Windlas Biotech Limited to Report Q3, 2026 Results on Feb 05, 2026Windlas Biotech Limited announced that they will report Q3, 2026 results on Feb 05, 2026
分析記事 • Jan 17Windlas Biotech Limited's (NSE:WINDLAS) Popularity With Investors Is Under Threat From OverpricingWith a median price-to-earnings (or "P/E") ratio of close to 25x in India, you could be forgiven for feeling...
分析記事 • Nov 14Solid Earnings May Not Tell The Whole Story For Windlas Biotech (NSE:WINDLAS)The market shrugged off Windlas Biotech Limited's ( NSE:WINDLAS ) solid earnings report. We think that investors might...
分析記事 • Nov 11Here's Why We Think Windlas Biotech (NSE:WINDLAS) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Reported Earnings • Nov 07Second quarter 2026 earnings released: EPS: ₹8.48 (vs ₹7.49 in 2Q 2025)Second quarter 2026 results: EPS: ₹8.48 (up from ₹7.49 in 2Q 2025). Revenue: ₹2.26b (up 21% from 2Q 2025). Net income: ₹178.0m (up 14% from 2Q 2025). Profit margin: 7.9% (down from 8.4% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 29Windlas Biotech Limited to Report Q2, 2026 Results on Nov 06, 2025Windlas Biotech Limited announced that they will report Q2, 2026 results on Nov 06, 2025
Reported Earnings • Aug 13First quarter 2026 earnings released: EPS: ₹8.43 (vs ₹6.47 in 1Q 2025)First quarter 2026 results: EPS: ₹8.43 (up from ₹6.47 in 1Q 2025). Revenue: ₹2.15b (up 23% from 1Q 2025). Net income: ₹176.6m (up 31% from 1Q 2025). Profit margin: 8.2% (up from 7.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 09Windlas Biotech Limited to Report Q1, 2026 Results on Aug 12, 2025Windlas Biotech Limited announced that they will report Q1, 2026 results on Aug 12, 2025
お知らせ • Jul 29Windlas Biotech Limited Approves Final Dividend for the Financial Year 2024-25Windlas Biotech Limited announced that at the AGM held on July 28, 2025 approved Final Dividend of INR 5.80/- per Equity Share for the financial year 2024-25.
分析記事 • Jul 22It Looks Like The CEO Of Windlas Biotech Limited (NSE:WINDLAS) May Be Underpaid Compared To PeersKey Insights Windlas Biotech's Annual General Meeting to take place on 28th of July Total pay for CEO Komal Gupta...
Upcoming Dividend • Jul 14Upcoming dividend of ₹5.80 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 27 August 2025. Payout ratio is a comfortable 20% and the cash payout ratio is 76%. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.4%).
お知らせ • Jul 06Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025Windlas Biotech Limited, Annual General Meeting, Jul 28, 2025, at 13:00 Indian Standard Time.
Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹29.19 (vs ₹27.97 in FY 2024)Full year 2025 results: EPS: ₹29.19 (up from ₹27.97 in FY 2024). Revenue: ₹7.78b (up 23% from FY 2024). Net income: ₹609.9m (up 4.8% from FY 2024). Profit margin: 7.8% (down from 9.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 14Windlas Biotech Limited to Report Q4, 2025 Results on May 22, 2025Windlas Biotech Limited announced that they will report Q4, 2025 results on May 22, 2025
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,070, the stock trades at a trailing P/E ratio of 36.2x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 318% over the past three years.
分析記事 • Mar 25Should You Be Adding Windlas Biotech (NSE:WINDLAS) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Feb 26Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹821, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 248% over the past three years.
分析記事 • Feb 19What You Can Learn From Windlas Biotech Limited's (NSE:WINDLAS) P/E After Its 28% Share Price CrashThe Windlas Biotech Limited ( NSE:WINDLAS ) share price has fared very poorly over the last month, falling by a...
Reported Earnings • Feb 12Third quarter 2025 earnings released: EPS: ₹7.45 (vs ₹7.26 in 3Q 2024)Third quarter 2025 results: EPS: ₹7.45 (up from ₹7.26 in 3Q 2024). Revenue: ₹1.95b (up 20% from 3Q 2024). Net income: ₹155.8m (up 3.2% from 3Q 2024). Profit margin: 8.0% (down from 9.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹842, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 52x in the Life Sciences industry in India. Total returns to shareholders of 227% over the past three years.
お知らせ • Feb 03Windlas Biotech Limited to Report Q3, 2025 Results on Feb 11, 2025Windlas Biotech Limited announced that they will report Q3, 2025 results on Feb 11, 2025
分析記事 • Jan 28Windlas Biotech (NSE:WINDLAS) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jan 10Windlas Biotech Limited Receives Good Manufacturing Practices Certification for New Injectable Facility from the Food Safety & Drugs Administration Authority of UttarakhandWindlas Biotech Limited announced that it has received Good Manufacturing Practices (GMP) certification for its new Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines.
分析記事 • Nov 20There May Be Underlying Issues With The Quality Of Windlas Biotech's (NSE:WINDLAS) EarningsDespite posting some strong earnings, the market for Windlas Biotech Limited's ( NSE:WINDLAS ) stock hasn't moved much...
Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹7.49 (vs ₹6.75 in 2Q 2024)Second quarter 2025 results: EPS: ₹7.49 (up from ₹6.75 in 2Q 2024). Revenue: ₹1.92b (up 26% from 2Q 2024). Net income: ₹156.6m (up 12% from 2Q 2024). Profit margin: 8.2% (down from 9.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Nov 05Windlas Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024Windlas Biotech Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,116, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 272% over the past three years.
分析記事 • Nov 01Windlas Biotech Limited's (NSE:WINDLAS) 30% Share Price Surge Not Quite Adding UpWindlas Biotech Limited ( NSE:WINDLAS ) shares have continued their recent momentum with a 30% gain in the last month...
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹998, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 51x in the Life Sciences industry in India. Total returns to shareholders of 203% over the past three years.
お知らせ • Sep 26Windlas Biotech Limited Approves Final Dividend for the Financial Year 2023-24Windlas Biotech Limited at its AGM held on September 24, 2024, approved final dividend of INR 5.50 per equity share for the financial year 2023-24.
分析記事 • Sep 01Windlas Biotech (NSE:WINDLAS) Will Pay A Larger Dividend Than Last Year At ₹5.50Windlas Biotech Limited's ( NSE:WINDLAS ) dividend will be increasing from last year's payment of the same period to...
Declared Dividend • Aug 31Dividend increased to ₹5.50Dividend of ₹5.50 is 38% higher than last year. Ex-date: 17th September 2024 Payment date: 24th October 2024 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 25% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 79% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years.
お知らせ • Aug 30Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024Windlas Biotech Limited, Annual General Meeting, Sep 24, 2024, at 14:30 Indian Standard Time.
お知らせ • Aug 29Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2023-24Windlas Biotech Limited at the AGM to be held on September 24, 2024, the shareholders proposed a final dividend of INR 5.50 per equity share for the financial year 2023-24.
Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹6.47 (vs ₹5.79 in 1Q 2024)First quarter 2025 results: EPS: ₹6.47 (up from ₹5.79 in 1Q 2024). Revenue: ₹1.79b (up 24% from 1Q 2024). Net income: ₹134.8m (up 12% from 1Q 2024). Profit margin: 7.5% (down from 8.3% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Aug 13Windlas Biotech Limited (NSE:WINDLAS) Stock Rockets 26% But Many Are Still Ignoring The CompanyDespite an already strong run, Windlas Biotech Limited ( NSE:WINDLAS ) shares have been powering on, with a gain of 26...
お知らせ • Aug 02Windlas Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024Windlas Biotech Limited announced that they will report Q1, 2025 results on Aug 13, 2024
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹798, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 42x in the Life Sciences industry in India. Total returns to shareholders of 142% over the past year.
分析記事 • Jul 30Should You Be Adding Windlas Biotech (NSE:WINDLAS) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
分析記事 • Jun 07Even With A 27% Surge, Cautious Investors Are Not Rewarding Windlas Biotech Limited's (NSE:WINDLAS) Performance CompletelyWindlas Biotech Limited ( NSE:WINDLAS ) shares have had a really impressive month, gaining 27% after a shaky period...
Reported Earnings • May 21Full year 2024 earnings released: EPS: ₹27.97 (vs ₹19.70 in FY 2023)Full year 2024 results: EPS: ₹27.97 (up from ₹19.70 in FY 2023). Revenue: ₹6.44b (up 26% from FY 2023). Net income: ₹581.9m (up 37% from FY 2023). Profit margin: 9.0% (up from 8.3% in FY 2023). The increase in margin was driven by higher revenue.
Buy Or Sell Opportunity • May 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.2% to ₹553. The fair value is estimated to be ₹457, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.
お知らせ • May 12Windlas Biotech Limited to Report Q4, 2024 Results on May 20, 2024Windlas Biotech Limited announced that they will report Q4, 2024 results on May 20, 2024
Buy Or Sell Opportunity • Apr 30Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to ₹553. The fair value is estimated to be ₹458, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.
Buy Or Sell Opportunity • Apr 22Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to ₹568. The fair value is estimated to be ₹462, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.
Buy Or Sell Opportunity • Apr 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to ₹559. The fair value is estimated to be ₹460, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.
New Risk • Mar 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.1% average weekly change).
Buy Or Sell Opportunity • Feb 23Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to ₹547. The fair value is estimated to be ₹456, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 26%.
Reported Earnings • Feb 09Third quarter 2024 earnings released: EPS: ₹7.26 (vs ₹4.23 in 3Q 2023)Third quarter 2024 results: EPS: ₹7.26 (up from ₹4.23 in 3Q 2023). Revenue: ₹1.65b (up 38% from 3Q 2023). Net income: ₹151.0m (up 64% from 3Q 2023). Profit margin: 9.1% (up from 7.7% in 3Q 2023). The increase in margin was driven by higher revenue.
お知らせ • Jan 31Windlas Biotech Limited to Report Q3, 2024 Results on Feb 08, 2024Windlas Biotech Limited announced that they will report Q3, 2024 results on Feb 08, 2024
Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹528, the stock trades at a trailing P/E ratio of 23.5x. Average trailing P/E is 22x in the Life Sciences industry in India. Total returns to shareholders of 118% over the past year.
Reported Earnings • Nov 14Second quarter 2024 earnings released: EPS: ₹6.75 (vs ₹5.59 in 2Q 2023)Second quarter 2024 results: EPS: ₹6.75 (up from ₹5.59 in 2Q 2023). Revenue: ₹1.56b (up 18% from 2Q 2023). Net income: ₹140.3m (up 15% from 2Q 2023). Profit margin: 9.0% (down from 9.2% in 2Q 2023). The decrease in margin was driven by higher expenses.
分析記事 • Nov 03Is Now The Time To Put Windlas Biotech (NSE:WINDLAS) On Your Watchlist?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
お知らせ • Oct 31Windlas Biotech Limited to Report First Half, 2024 Results on Nov 08, 2023Windlas Biotech Limited announced that they will report first half, 2024 results on Nov 08, 2023
お知らせ • Sep 13Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23Windlas Biotech Limited at the AGM held on September 12, 2023, the shareholders approved a final dividend of INR 4 per equity share for the financial year 2022-23.
Upcoming Dividend • Aug 29Upcoming dividend of ₹4.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 05 September 2023. Payment date: 12 October 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.6%).
分析記事 • Aug 20Windlas Biotech (NSE:WINDLAS) Is Increasing Its Dividend To ₹4.00Windlas Biotech Limited's ( NSE:WINDLAS ) dividend will be increasing from last year's payment of the same period to...
お知らせ • Aug 19+ 1 more updateWindlas Biotech Limited, Annual General Meeting, Sep 12, 2023Windlas Biotech Limited, Annual General Meeting, Sep 12, 2023, at 12:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2023, together with the Reports of the Auditors and the Board of Directors thereon; to consider declare a Final Dividend; to consider and appoint a Director in place of Mr. Hitesh Windlass, Managing Director who is liable to retire by rotation and being eligible, offers himself for re-appointment; and to transact such other business matters.
Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹384, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 82% over the past year.
Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: ₹5.79 (vs ₹4.50 in 1Q 2023)First quarter 2024 results: EPS: ₹5.79 (up from ₹4.50 in 1Q 2023). Revenue: ₹1.47b (up 23% from 1Q 2023). Net income: ₹120.7m (up 23% from 1Q 2023). Profit margin: 8.2% (in line with 1Q 2023).
お知らせ • Aug 01Windlas Biotech Limited to Report Q1, 2024 Results on Aug 08, 2023Windlas Biotech Limited announced that they will report Q1, 2024 results on Aug 08, 2023
Reported Earnings • May 06Full year 2023 earnings released: EPS: ₹19.70 (vs ₹18.58 in FY 2022)Full year 2023 results: EPS: ₹19.70 (up from ₹18.58 in FY 2022). Revenue: ₹5.23b (up 12% from FY 2022). Net income: ₹426.3m (up 12% from FY 2022). Profit margin: 8.1% (down from 8.2% in FY 2022). The decrease in margin was driven by higher expenses.
お知らせ • May 06Windlas Biotech Limited Recommends DividendWindlas Biotech Limited at its board meeting held on May 5, 2023 Recommended a Dividend of INR 4.00/- per Equity Share of face value of INR 5/- each. The said dividend, if declared by the Members of the Company at the ensuing Annual General Meeting (AGM), will be credited/despatched within three weeks of the conclusion of said AGM.
お知らせ • Feb 10Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive OfficerWindlas Biotech Limited announced that on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on February 08, 2023, approved the appointment of Ms. Komal Gupta as the Chief Executive Officer and Key Managerial Personnel of the Company with effect from February 08, 2023. Ms. Komal Gupta holds a bachelor's degree in commerce from Dr. Babasaheb Ambedkar Marathwada University. She is a fellow member of the Institute of Chartered Accountants of India, an associate member of the Institute of Company Secretaries of India and the Institute of Cost and Works Accountants of India. She has experience in the field of finance. She joined the Company on October 16, 2015. She is currently the Chief Financial Officer of the Company and she will continue as Chief Financial Officer till a suitable person is appointed. Ms. Komal Gupta has an extensive experience in the field of Finance, Accounts, Taxation, Business Finance, Treasury and Compliance. Prior to joining the Company, she has worked with Anand Automotives Group (Perfect Circle India Limited, Mahle Filters Limited, Corporate office Anand Automotive Systems Limited) and DSM Group (DSM Sinochem Pharmaceuticals India Pvt. Ltd., now Centrient Pharmaceuticals India Pvt. Ltd.).
Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: ₹4.23 (vs ₹3.81 in 3Q 2022)Third quarter 2023 results: EPS: ₹4.23 (up from ₹3.81 in 3Q 2022). Revenue: ₹1.22b (up 3.6% from 3Q 2022). Net income: ₹91.9m (up 11% from 3Q 2022). Profit margin: 7.5% (up from 7.1% in 3Q 2022). The increase in margin was driven by higher revenue.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 09Second quarter 2023 earnings released: EPS: ₹5.59 (vs ₹4.11 in 2Q 2022)Second quarter 2023 results: EPS: ₹5.59 (up from ₹4.11 in 2Q 2022). Revenue: ₹1.35b (up 17% from 2Q 2022). Net income: ₹121.9m (up 47% from 2Q 2022). Profit margin: 9.0% (up from 7.2% in 2Q 2022). The increase in margin was driven by higher revenue.
お知らせ • Aug 27+ 1 more updateWindlas Biotech Limited to Report Fiscal Year 2023 Results on May 30, 2023Windlas Biotech Limited announced that they will report fiscal year 2023 results on May 30, 2023
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹4.50 (vs ₹3.67 in 1Q 2022)First quarter 2023 results: EPS: ₹4.50 (up from ₹3.67 in 1Q 2022). Revenue: ₹1.23b (up 11% from 1Q 2022). Net income: ₹98.0m (up 47% from 1Q 2022). Profit margin: 8.0% (up from 6.0% in 1Q 2022). The increase in margin was driven by higher revenue.
分析記事 • May 23Windlas Biotech (NSE:WINDLAS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfWindlas Biotech Limited's ( NSE:WINDLAS ) robust earnings report didn't manage to move the market for its stock. We did...
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹243, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 36x in the Life Sciences industry in India.
分析記事 • Apr 07Windlas Biotech Limited's (NSE:WINDLAS) Shares Lagging The Market But So Is The BusinessWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 22x, you may consider...
Reported Earnings • Feb 03Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹3.81 (down from ₹6.75 in 3Q 2021). Revenue: ₹1.19b (up 1.0% from 3Q 2021). Net income: ₹83.1m (down 32% from 3Q 2021). Profit margin: 7.0% (down from 10% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.
Reported Earnings • Sep 12First quarter 2022 earnings released: EPS ₹3.67 (vs ₹0.25 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹1.11b (up 50% from 1Q 2021). Net income: ₹66.9m (up ₹62.2m from 1Q 2021). Profit margin: 6.0% (up from 0.6% in 1Q 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹398, the stock trades at a trailing P/E ratio of 39.6x. Average trailing P/E is 45x in the Life Sciences industry in India.
Board Change • Aug 17Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Non-Executive Independent Director Gaurav Gulati was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.